Key result
Staphylococcal vesicles with DENV antigens induce four-serotype antibodies and protect mice from lethal DENV-2.
Engineered staphylococcal membrane vesicles can successfully deliver heterologous viral antigens and induce protective multivalent immune responses in preclinical models.
Answers are grounded in this paper and cite their sources.
Advances multivalent dengue vaccine strategies in preclinical models; leaves open human translation and efficacy testing.
Many viruses often have closely related yet antigenically distinct serotypes. An ideal vaccine against viral infections should induce a multivalent and protective immune response against all serotypes. Inspired by bacterial membrane vesicles (MVs) that carry different protein components, we constructed an agr locus deletion mutant of the Staphylococcus aureus strain (RN4220-Δagr) to reduce potential toxicity. Nanoscale vesicles derived from this strain (ΔagrMVs) carry at least four major components that can deliver heterologous antigens. These components were each fused with a triple FLAG tag, and the tagged proteins could be incorporated into the ΔagrMVs. The presentation levels were (3.43 ± 0.73)%, (5.07 ± 0.82)%, (2.64 ± 0.61)%, and (2.89 ± 0.74)% of the total ΔagrMV proteins for Mntc-FLAG, PdhB-FLAG, PdhA-FLAG, and Eno-FLAG, respectively. With two DENV envelope E domain III proteins (EDIIIconA and EDIIIconB) as models, the DENV EDIIIconA and EDIIIconB delivered by two staphylococcal components were stably embedded in the ΔagrMVs. Administration of such engineered ΔagrMVs in mice induced antibodies against all four DENV serotypes. Sera from immunized mice protected Vero cells and suckling mice from a lethal challenge of DENV-2. This study will open up new insights into the preparation of multivalent nanosized viral vaccines against viral infections.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2017) studied Viral infections (Dengue virus). Engineered ΔagrMVs delivering DENV EDIIIconA and EDIIIconB was evaluated on Induction of antibodies against DENV serotypes and protection from lethal challenge of DENV-2. Administration of engineered staphylococcal nanoscale vesicles delivering DENV antigens in mice induced antibodies against all four DENV serotypes and protected against a lethal DENV-2 challenge.
Synapse has enriched 10 related papers. Consider them for comparative context: